Evidence map›Paper›PMID 36514116›Full record

Observational studyArthritis research & therapy2022

Outcome of adult patients with JIA treated with the biosimilar Benepali

Kristina Vollbach, Klaus Tenbrock, Nobert Wagner, Gerd Horneff, Ariane Klein, Ivan Foeldvari, Johannes-Peter Haas, Peer Aries, Georg Gauler, Frank Striesow and 6 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Arthritis research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 1 country.

Kristina VollbachDepartment of Pediatrics, RWTH Aachen University Hospital, Aachen, Germany.
Klaus TenbrockDepartment of Pediatrics, RWTH Aachen University Hospital, Aachen, Germany.
Nobert WagnerDepartment of Pediatrics, RWTH Aachen University Hospital, Aachen, Germany.
Gerd HorneffCentre for Pediatric Rheumatology, Department of Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany.
Ariane KleinCentre for Pediatric Rheumatology, Department of Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany.
Ivan FoeldvariZentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany.
Johannes-Peter HaasGerman Centre for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany.
Peer AriesRheumatologie im Struenseehaus, Hamburg, Germany.
Georg GaulerRheumapraxis an der Hase, Osnabrück, Germany.
Frank StriesowInternistisch-Rheumatologische Praxis, Bonn, Germany.
Paula HoffMVZ Endokrinologikum Berlin am Gendarmenmarkt, Berlin, Germany.
Christine ScholzInternistisch-Rheumatologische Praxis, Freiburg, Germany.
Stefanie TatsisMarienkrankenhaus, Hamburg, Germany.
Eva SeipeltImmanuel Krankenhaus, Berlin Buch, Germany.
Jens Klotsche *Deutsches Rheuma-Forschungszentrum Berlin, Leibniz Association, Berlin, Germany.
Kirsten Minden *Deutsches Rheuma-Forschungszentrum Berlin, Leibniz Association, Berlin, Germany. minden@drfz.de.
Universitätsklinikum Aachen · DEGerman Rheumatism Research Centre · DEUniversity Hospital Cologne · DEDermatologie Freiburg · DEEndokrinologikum · DEGerman Center for Pediatric and Adolescent Rheumatology · DEImmanuel Krankenhaus · DEKinderkrebs-Zentrum Hamburg · DEMarienkrankenhaus Hamburg · DEOrthopädische Praxis · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo analyze therapy adherence, safety, and outcome in adult patients with juvenile idiopathic arthritis (JIA) treated with the etanercept biosimilar Benepali

methodsData from the prospective registry, JuMBO (Juvenile arthritis MTX/Biologics long-term Observation), were used for the analysis. JuMBO is a long-term observational cohort study. It follows adult patients with JIA who were formerly included in the national JIA biologic register (BiKeR Registry). Both registries provide individual trajectories of clinical data and outcomes from childhood to adulthood in JIA patients treated with disease-modifying anti-rheumatic drugs (DMARDs).

resultsEighty-three patients from the German JuMBO registry were treated with Benepali

conclusionsTolerability and effectiveness of the biosimilar Benepali

Indexed as

Antirheumatic AgentsArthritis, JuvenileBiosimilar PharmaceuticalsAdolescentAdultChildEtanerceptHumansRegistriesTreatment OutcomeYoung AdultAntirheumatic AgentsBiosimilar PharmaceuticalsEtanerceptBenepali®BiosimilarEffectivenessEnbrel®EtanerceptJuvenile idiopathic arthritisTherapy survival

Identifiers

PMID36514116
PMCPMC9746218
OpenAlexW4311225685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.